A method of forming a shoulder prosthesis includes resecting an end portion of a humerus to form a resected end of the humerus and a resected portion separated from the humerus, the resected portion having an outer convex surface and an inner surface. The inner surface of the resected portion is processed to include a concave articular surface. The outer convex surface of the resected portion is implanted in the resected end of the humerus. An implant having a convex articular surface is secured to a glenoid. The concave articular surface of the resected portion is articulated with the convex articular surface of the implant.

The invention relates to an arrangement (1) comprising at least one structural element (2) made of an absorbable material with an antibacterial effect with a mount, which possesses an aspect ratio greater than 10 and whereat the material is a rapidly corroding magnesium alloy. The invention further relates to a mount (10) with an arrangement (1) carried by the mount (10) comprising at least one structural element (2) made of an absorbable material with an antibacterial effect.

A low profile implant, system and method of deployment includes a frame comprising an elongate body having ends that overlap to form an annular configuration of the frame. A circumference of the frame may be modified by varying an extent of the overlap between the ends of the elongate body. The elongate structure may extend through a sleeve of a number of respective anchor housings of the implant along a first axis, and anchors may be deployed through bores in the anchor housings along a second axis to secure the anchor housings to tissue. The implant may be deployed about and anchored to a valve annulus, and the circumference of the frame, and associated anchored tissue, may be adjusted to reconfigure the valve annulus.

Provided are orthopedic implants and systems and kits containing orthopedic implants that include biodegradable polymer thin films containing an antimicrobial agent, wherein the implants produce an effective zone of inhibition around a periphery of the surface of the implant and do not produce a loss of release torque between interlocking implant components.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

The present invention relates to an implant (10) comprising an implant body having a first surface area (A1, A2, A3, A4) configured for contact with soft connective tissue and a second surface area configured for contact with bone tissue, wherein the first surface area is covered with a coating comprising tantalum and the second surface area is formed by a material, which is different than the one forming the coating.

The invention provides medical devices comprising high-strength alloys which degrade over time in the body of a human or animal, at controlled degradation rates, without generating emboli and which have enhanced degradation due to the presence of a halogen component. In one embodiment the alloy is formed into a bone fixation device such as an anchor, screw, plate, support or rod. In another embodiment the alloy is formed into a tissue fastening device such as staple. In yet another embodiment, the alloy is formed into a dental implant or a stent.

An exchangeable optics system includes an intraocular base that can be fixed within an eye. The intraocular base includes one or more couplers and a supporting structure. The one or more couplers releasably couple to an exchangeable optic and can include magnetic material. The supporting structure can include haptics and a main structure that physically supports the exchangeable optic. The intraocular base can include a fixed lens within or on the main structure. The exchangeable optic can include corresponding one or more couplers, which may be formed of magnetic material.

The present disclosure is directed to a medical device for inhibiting the activity of bacterial collagenase and/or a matrix metalloproteinase (MMP). In some embodiments, the medical device comprises a polymer that includes a transition metal or a salt thereof. In some embodiments, the medical device comprises an alloy that has at least one of a transition metal or a transition metal salt.